Provectus Therapeutics

Project Leader(s):
Mr. Man-kin SUEN
Key Technology Area:
Industrial Sector(s):
Pharmaceutical and Healthcare Products
Click here to contact us


Provectus Therapeutics has developed the Next Generation Drug Screening AI Platform for in-depth tumor analysis, high-throughput drug screening, and phenotypic analysis at the single-cell level by implementing Artificial Intelligence and Microfluidics. Morphological and phenotypic responses will be extracted from over 1 million single cancer cells using a proprietary Artificial Intelligence algorithm for drug resistance analysis. This provides unprecedented resolution in solid tumor analysis for novel therapeutic biomarker identification, early-stage preclinical testing, and personalized treatment prediction.